Transaction #13873 · Form 4 · 0001193125-25-303910
Rapport Therapeutics, Inc. · Exercise / conversion · Common Stock
Rapport Therapeutics, Inc. · Transacted November 26, 2025 · Filed December 1, 2025
What does this filing report?
An SEC Form 4 filing for Rapport Therapeutics, Inc. records an exercise / conversion involving Common Stock on November 26, 2025. The reported quantity was 5,000. The filing date is December 1, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Rapport Therapeutics, Inc.
- Company CIK
- 0002012593
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 5,000
- Reported price
- 1.8
- Reference value
- 9,000
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 176,928
- Ownership description
- Not reported
- SEC acceptance time
- Dec 1, 2025, 4:17 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Gault Cheryl ↗
Chief Operating Officer
CIK 0001839046
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024.
- F2
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3
- 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.